MAPT and Cognitive impairment: GLP-1 analogs reduce amyloid and tau pathologies, inflammation, and cognitive impairment in different models (McClean et al., 2011; Chen et al., 2017; Batista et al., 2018; Duarte et al., 2020; Jantrapirom et al., 2020).